acetylgalactosamine has been researched along with Liver Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Holm, A; Kauppinen, S; Løvendorf, MB | 1 |
| Hu, B; Huang, Y; Lu, M; Zhang, M | 1 |
| Bocci, V | 1 |
2 review(s) available for acetylgalactosamine and Liver Dysfunction
| Article | Year |
|---|---|
Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Topics: Acetylgalactosamine; Amyloid Neuropathies, Familial; Animals; Gene Transfer Techniques; Humans; Liver Diseases; Porphyrias, Hepatic; Pyrrolidines; RNA Interference; RNA, Small Interfering; RNAi Therapeutics | 2021 |
The role of sialic acid in determining the life-span of circulating cells and glycoproteins.
Topics: Acetylgalactosamine; alpha-Macroglobulins; Animals; Blood Cells; Bone Marrow; Cell Membrane; Ceruloplasmin; Erythrocyte Aging; Erythrocytes; Feedback; Glycoproteins; Haptoglobins; Hemolysis; Humans; Immunoglobulin G; Liver; Liver Diseases; Neuraminidase; Orosomucoid; Rabbits; Sialic Acids; Spleen; Transferrin | 1976 |
1 other study(ies) available for acetylgalactosamine and Liver Dysfunction
| Article | Year |
|---|---|
siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.
Topics: Acetylgalactosamine; Animals; Gene Transfer Techniques; HEK293 Cells; Hepatocytes; Humans; Liver; Liver Diseases; Mice, Inbred C57BL; Prealbumin; Research Design; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Toxicity Tests; Workflow | 2021 |